Valuation: Karyopharm Therapeutics Inc.

Market Cap 44.65M 38.8M 36.23M 33.26M 62.71M 4.26B 63.8M 427M 167M 2.12B 168M 164M 7B P/E 2026 *
-0.45x
P/E 2027 * -0.72x
Enterprise Value 44.65M 38.8M 36.23M 33.26M 62.71M 4.26B 63.8M 427M 167M 2.12B 168M 164M 7B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.26x
Free-Float
95.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day+2.60%
1 week-72.21%
Current month+2.60%
1 month-79.48%
3 months-77.54%
6 months-69.92%
Current year-73.23%
1 week 1.8
Extreme 1.8
7.47
1 month 1.8
Extreme 1.8
10.86
Current year 1.8
Extreme 1.8
10.99
1 year 1.8
Extreme 1.8
10.99
3 years 1.8
Extreme 1.8
29.25
5 years 1.8
Extreme 1.8
220.95
10 years 1.8
Extreme 1.8
444.15
Manager TitleAgeSince
Chief Executive Officer 58 2021-05-02
Director of Finance/CFO 55 2025-01-02
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Director/Board Member 62 2012-12-31
Director/Board Member 61 2013-03-31
Director/Board Member 78 2013-10-02
Date Insider Type Main position Quantity % Market Cap.
7/28/26 Sell

Executive/Senior Manager

-189 0.0008%
5/14/26 Sell

Controller/Auditor

-53 0.0002%
2/17/26 Sell

Executive/Senior Manager

378 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+2.60%-72.21%-49.87%-92.74% 44.65M
-0.44%+13.80%+35.85%-1.58% 75.81B
+2.08%-9.43%+22.72%+184.82% 48.57B
-4.18%+42.30%+42.30%+42.30% 46.01B
+3.64%+7.79%-51.37%-51.41% 41.66B
-0.56%+0.84%+52.95%-24.62% 29.82B
-0.91%-0.37%+56.67%+82.26% 24.01B
+0.58%-0.88%+99.75%-49.85% 22.01B
+0.70%-3.62%-6.73%+164.18% 19.09B
+0.09%-6.68%+61.45%+115.43% 15.83B
Average +0.39%-7.99%+26.37%+36.88% 32.29B
Weighted average by Cap. +0.09%+0.93%+29.75%+42.62%

Financials

2026 *2027 *
Net sales 134M 116M 109M 99.62M 188M 12.75B 191M 1.28B 501M 6.36B 502M 491M 20.97B 175M 152M 142M 130M 245M 16.64B 250M 1.67B 654M 8.3B 656M 641M 27.38B
Net income -118M -103M -95.77M -87.92M -166M -11.25B -169M -1.13B -442M -5.61B -443M -434M -18.5B -105M -91.17M -85.12M -78.14M -147M -10B -150M -1B -393M -4.99B -394M -385M -16.45B
Net Debt - -
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
26-08-03 US$1.970 +2.60% 4,514,606
26-07-31 US$1.920 -72.61% 22,398,319
26-07-30 US$7.010 +2.19% 4,540,851
26-07-29 US$6.860 -3.24% 436,891
26-07-28 US$7.090 0.00% 531,286
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.970USD
Average target price
6.400USD
Spread / Average Target
+224.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KPTI Stock